Italfarmaco's rare disease unit includes programmes in Duchenne muscular dystrophy, Becker muscular dystrophy, amyotrophic lateral sclerosis and polycythaemia vera.

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going ...

It is designed to address the root cause of dystrophinopathies, such as Duchenne muscular dystrophy and Becker muscular dystrophy. A Scotiabank analyst recently initiated coverage on Edgewise with ...

This year's Futures National Conference, hosted by CureDuchenne for the Duchenne and Becker MD communities, is scheduled to ...

The Parent Project Muscular Dystrophy (PPMD ... setback is part of the journey toward advancing therapies for Duchenne and Becker, and we draw strength from the resilience and courage of our ...

Edgewise intends to use the net proceeds from the offering to support the potential U.S. commercial launch of sevasemten in patients with Becker ... in Duchenne muscular dystrophy, Phase 3 trials ...

Its lead drug, EDG-5506, aims to prevent muscle damage in patients with Duchenne and Becker muscular dystrophy. The Boulder, Colorado-based company also develops EDG-7500 for hypertrophic ...